Evidence map›Paper›PMID 28271340›Full record

ReviewMolecular biotechnology2017

An Overview on the Enhancement of Enantioselectivity and Stability of Microbial Epoxide Hydrolases.

Priya Saini, Dipti Sareen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Epoxide Hydrolases: Multipotential Biocatalysts.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Gram-Scale Synthesis of (Frontiers in bioengineering and biotechnology · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Complete Genome Sequence ofGenome announcements · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Priya SainiDepartment of Biochemistry, Panjab University, Sector 25, BMS Block II, Chandigarh, 160014, India.
Dipti SareenDepartment of Biochemistry, Panjab University, Sector 25, BMS Block II, Chandigarh, 160014, India. diptsare@pu.ac.in.
Panjab University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epoxide hydrolases (EHs; 3.3.2.x) catalyze the enantioselective ring opening of racemic epoxides to the corresponding enantiopure vicinal diols and remaining equivalent unreacted epoxides. These epoxides and diols are used for the synthesis of chiral drug intermediates. With an upsurge in the methods for identification of novel microbial EHs, a lot of EHs have been discovered and utilized for kinetic resolution of racemic epoxides. However, there is still a constraint on the account of limited EHs being successfully applied on the preparative scale for industrial biotransformations. This limitation has to be overcome before application of identified functional EHs on large scale. Many strategies such as optimizing reaction media, immobilizing EHs and laboratory-scale directed evolution of EHs have been adopted for enhancing the industrial potential of EHs. In this review, these approaches have been highlighted which can serve as a pathway for the enrichment of already identified EHs for their application on an industrial scale in future studies.

Indexed as

BacteriaBiocatalysisEnzyme StabilityEpoxide HydrolasesEpoxy CompoundsFungiProtein EngineeringStereoisomerismSubstrate SpecificityEpoxide HydrolasesEpoxy CompoundsDeep eutectic solventsEpoxide hydrolaseImmobilization and directed evolutionIonic liquidsOrganic solvents

Identifiers

PMID28271340
OpenAlexW2591765471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.